Arterial hypertension and breast cancer in women: mechanisms of comorbidity and iatrogenic disease
https://doi.org/10.18705/1607-419X-2022-28-2-147-156
Abstract
The combination of hypertension (HTN) and breast cancer (BC) is one of the most frequent clinical variants of comorbidity of cardiovascular and oncological diseases. Each of these pathologies is associated with risk factors, which are cross-cutting. The review presents an analysis of pathophysiological processes characterizing the nonrandomness of the co-existence of HTN and BC (chronic systemic inflammation, oxidative stress, endothelial and mitochondrial dysfunction, accelerated cellular aging, and other). Antitumor therapy of BC is often associated with vasculotoxic effects that provoke a transient or sustained increase in blood pressure. Adverse cardiovascular events may interfere with the implementation of antitumor therapy of BC. Interdisciplinary cooperation of cardiologists and oncologists in HTN and BC comorbidity will allow personifying algorithms for the prevention, diagnosis and treatment of these pathologies.
Supporting agencies: With partial financial supportprovided by the Russian Foundation for Basic Research (RFBR) for research project No. 19–29–01077.
About the Authors
T. A. Brodskaya
Far Eastern Federal University;
Pacific State Medical University
Russian Federation
Russian Federation
Tatyana A. Brodskaya, MD, PhD, DSc, Associate Professor, Director, Department of Clinical Medicine, School of Medicine, the Far Eastern Federal University, Professor, Institute of Therapy and Instrumental Diagnostics, Pacific State Medical University
i. Russkiy, v. Ayaks, Vladivostok, 690922
B. I. Geltser
Far Eastern Federal University
Russian Federation
Russian Federation
Boris I. Geltser, MD, PhD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Deputy Director for Scientific Work, School of Medicine
Vladivostok
T. S. Satalkina
Far Eastern Federal University
Russian Federation
Russian Federation
Tatyana S. Satalkina, MD, Postgraduate Student, Department of Clinical Medicine, School of Medicine
Vladivostok
S. V. Knysh
Far Eastern Federal University;
Pacific State Medical University
Russian Federation
Russian Federation
Sergey V. Knysh, MD, PhD, Associate Professor, Department of Clinical Medicine, School of Medicine, the Far Eastern Federal University, Associate Professor, Department of Normal and Pathological Physiology, Pacific State Medical University
Vladivostok
O. I. Shekunova
Far Eastern Federal University
Russian Federation
Russian Federation
Olga I. Shekunova, MD, PhD, Associate Professor, Department of Clinical Medicine, School of Medicine, Head, Therapeutic Center, Medical Center
Vladivostok
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
2. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM et al. GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021. doi:10.1016/j.jacc.2020.11.010
3. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–237. doi:10.1038/s41581-019-0244-2
4. Kobalava ZD, KonradiAO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786. In Russian.
5. Tini G, Sarocchi M, Tocci G, Arboscello E, Ghigliotti G, Novo G et al. Arterial hypertension in cancer: The elephant in the room. Int J Cardiol. 2019;281:133–139. doi:10.1016/j.ijcard.2019.01.082
6. Kaprin AD, Starinskii VV, Shakhzadova AO. Malignant neoplasms in Russia in 2019 (morbidity and mortality). M.: P. Hertsen MORI— branch of the “NMRC of Radiology” of the Ministry of Health of the Russian Federation. 2020. 252 p. In Russian.
7. Mouhayar E, Salahudeen A. Hypertension in cancer patients. Tex Heart Inst J. 2011;38(3):263–265.
8. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. doi:10.3322/caac.21349
9. Gernaat SAM, Ho P J, Rijnberg N, Emaus MJ, Baak LM, Hartman M et al. Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat. 2017;164(3):537–555. doi:10.1007/s10549-017-4282-9
10. Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016;27(1):6–13. doi:10.1097/EDE.0000000000000394
11. Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66(4):337– 350. doi:10.3322/caac.21342
12. Lüscher TF. Tumours and the heart: common risk factors, chemotherapy, and radiation. Eur Heart J. 2016;37(36):2737–2738. doi:10.1093/eurheartj/ehw451
13. Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in cancer patients and survivors: epidemiology, diagnosis, and management. JACC CardioOncol. 2019;1(2):238–251. doi:10.1016/j.jaccao.2019.11.009
14. Versmissen J, Mirabito Colafella KM, Koolen SLW, Danser AHJ. Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension. Cardiovasc Res. 2019;115(5):904– 914. doi:10.1093/cvr/cvz022
15. Escalante CP, Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. Cardiol Res Pract. 2011;2011:816897. doi:10.4061/2011/816897
16. Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J et al. Mechanisms of VEGF (Vascular Endothelial Growth Factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018;71(2):e1–e8. doi:10.1161/HYPERTENSIONAHA.117.10271
17. Johnson CB, Davis MK, Law A, Sulpher J. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can J Cardiol. 2016;32(7):900–907. doi:10.1016/j.cjca.2016.04.008
18. Fraeman KH, Nordstrom BL, Luo W, Landis SH, Shantakumar S. Incidence of new-onset hypertension in cancer patients: a retrospective cohort study. Int J Hypertens. 2013;2013:379252. doi:10.1155/2013/379252
19. Dyer AR, Stamler J, Berkson DM, Lindberg HA, Stevens E. High blood pressure: a risk factor for cancer mortality. Lancet. 1975;1(7915):1051–1056. doi:10.1016/s0140-6736(75)91826-7
20. Lindgren AM, Nissinen AM, Tuomilehto JO, Pukkala E. Cancer pattern among hypertensive patients in North Karelia, Finland. J Hum Hypertens. 2005;19(5):373–379. doi:10.1038/sj.jhh.1001834
21. Podkowa N, Komasińska P, Roszak M, Gryczka R, Grodecka-Gazdecka S, Łacka K. Health behaviours among women diagnosed with breast tumours. Pol Merkur Lekarski. 2014;37(219):153–158.
22. Seretis A, Cividini S, Markozannes G, Tseretopoulou X, Lopez DS, Ntzani EE et al. Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. Sci Rep. 2019;9(1):8565. doi:10.1038/s41598-019-45014-4
23. Han H, Guo W, Shi W, Yu Y, Zhang Y, Ye X et al. Hypertension and breast cancer risk: a systematic review and meta-analysis. Sci Rep. 2017;7:44877. doi:10.1038/srep44877
24. Wang W, He Q, Zhang H, Zhuang C, Wang Q, Li C et al. A narrative review on the interaction between genes and the treatment of hypertension and breast cancer. Ann Transl Med. 2021;9(10):894. doi:10.21037/atm21-2133
25. Vasyuk YuA, Gendlin GE, Emelina EI, Shupenina EYu, Ballyuzek MF, Barinova IV et al. Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology. 2021;26(9):4703. doi:10.15829/1560-4071-2021-4703. In Russian.
26. Kobalava ZD, Shavarova EK. Hypertension related to the antitumor treatment with angiogenesis inhibitors: an iatrogenic hypertension. Arterial’naya Gipertenziya = Arterial Hypertension. 2018;24(4):384–395. doi:10.18705/1607-419X2018-24-4-384-395. In Russian.
27. Gel’tser ВI, Kotel’nikov VN, Vetrova ОО, Karpov RS. Masked arterial hypertension: prevalence, pathophysiological determinants and clinical significance. Russian Journal of Cardiology l. 2019;(9):92–98. doi:10.15829/1560-4071-2019-9-92-98. In Russian.
28. Oshchepkova EV, Avalyan AA, Rogoza AN, Gorieva SB, Saidova MA, Chazova IE. Uncontrolled arterial hypertension in patients with breast cancer and the risk of developing cardiotoxicity with anthracycline-containing chemotherapy. Sistemnye Gipertenzii = Systemic Hypertension. 2019;16(4):38–44. doi:10.26442/2075082X.2019.4.190614. In Russian.
29. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30–e66. doi:10.1161/CIR.0000000000000556
30. van Westerop LLM, Arts-de Jong M, Hoogerbrugge N, de Hullu JA, Maas AHEM. Cardiovascular risk of BRCA1/2 mutation carriers: a review. Maturitas. 2016;91:135–139. doi:10.1016/j.maturitas.2016.06.012
31. Arts-de Jong M, Maas AH, Massuger LF, Hoogerbrugge N, de Hullu JA. BRCA1/2 mutation carriers are potentially at higher cardiovascular risk. Crit Rev Oncol Hematol. 2014;91(2):159–171. doi:10.1016/j.critrevonc.2014.01.008
32. Kushi LH, Doyle C, McCullough M, Rock CL, DemarkWahnefried W, Bandera EV et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention. CA Cancer J Clin. 2012;62(1):30–67. doi:10.3322/caac.20140
33. Heidemann C, Schulze MB, Franco OH, van Dam RM, Mantzoros CS, Hu FB. Dietary patterns and risk of mortality from cardiovascular disease, cancer, and all causes in a prospective cohort of women. Circulation. 2008;118(3):230–237. doi:10.1161/CIRCULATIONAHA.108.771881
34. Radkevich LA, Radkevich, DA. The dietary patterns and the risk of breast cancer. Res Pract Med J. 2016;3(3):30–41. doi:10.17709/2409-2231-2016-3-3-3. In Russian.
35. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT; Lancet Physical Activity Series Working Group. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380(9838):219–229. doi:10.1016/S0140-6736(12)61031-9
36. Loprinzi PD, Cardinal BJ, Smit E, Winters-Stone KM. Physical activity and breast cancer risk. J Exers Sci Fit. 2012;10:1–7. doi:10.1016/j.jesf.2012.04.004
37. Boeke CE, Eliassen AH, Oh H, Spiegelman D, Willett WC, Tamimi RM. Adolescent physical activity in relation to breast cancer risk. Breast Cancer Res Treat. 2014;145(3):715–724. doi:10.1007/s10549-014-2919-5
38. Kaplan RC, Baldoni PL, Strizich GM, Pérez-Stable EJ, Saccone NL, Peralta CA et al. Current smoking raises risk of incident hypertension: Hispanic Community Health Study — Study of Latinos. Am J Hypertens. 2021;34(2):190–197. doi:10.1093/ajh/hpaa152
39. Xue F, Willett WC, Rosner BA, Hankinson SE, Michels KB. Cigarette smoking and the incidence of breast cancer. Arch Intern Med. 2011;171(2):125–133. doi:10.1001/archinternmed.2010.503
40. Cotterchio M, Mirea L, Ozcelik H, Kreiger N. Active cigarette smoking, variants in carcinogen metabolism genes and breast cancer risk among pre- and postmenopausal women in Ontario, Canada. Breast J. 2014;20(5):468–480. doi:10.1111/tbj.12304
41. Charalampopoulos D, McLoughlin A, Elks CE, Ong KK. Age at menarche and risks of all-cause and cardiovascular death: a systematic review and meta-analysis. Am J Epidemiol. 2014;180(1): 29–40. doi:10.1093/aje/kwu113
42. Mueller NT, Odegaard AO, Gross MD, Koh WP, Yuan JM, Pereira MA. Age at menarche and cardiovascular disease mortality in Singaporean Chinese women: the Singapore Chinese Health Study. Ann Epidemiol. 2012;22(10):717–722. doi:10.1016/j.annepidem.2012.08.002
43. Wellons M, Ouyang P, Schreiner PJ, Herrington DM, Vaidya D. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause. 2012;19(10):1081–1087. doi:10.1097/gme.0b013e3182517bd0
44. Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575–584. doi:10.1016/j.cjca.2017.12.005
45. Biello F, Platini F, D’Avanzo F, Cattrini C, Mennitto A, Genestroni S et al. Insulin/IGF axis in breast cancer: clinical evidence and translational insights. Biomolecules. 2021;11(1):125. doi:10.3390/biom11010125
46. Ballotari P, Vicentini M, Manicardi V, Gallo M, Chiatamone Ranieri S, Greci M et al. Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy. BMC Cancer. 2017;17(1):703. doi:10.1186/s12885-017-3696-4
47. Christopoulos PF, Msaouel P, Koutsilieris M. The role of the insulin-like growth factor1 system in breast cancer. Mol Cancer. 2015;14:43. doi:10.1186/s12943-015-0291-7
48. Misnikova IV. Diabetes and cancer. Russian Medical Journal. 2016;20:1346–1350. In Russian.
49. Orlova NV, Starokozheva AY, Timoshchenko AV. Psychoemotional stress in review of ESC/ESH recommendations for treatment of hypertension (2018) and clinical trial results. Meditsinskii alfavit = Med Alph. 2019;2(30):44–47. doi:10.33667/2078-5631-2019-2-30(405)-44-47. In Russian.
50. Antonova L, Aronson K, Mueller CR. Stress and breast cancer: from epidemiology to molecular biology. Breast Cancer Res. 2011;13(2):208. doi:10.1186/bcr2836
51. Chiriac VF, Baban A, Dumitrascu DL. Psychological stress and breast cancer incidence: a systematic review. Clujul Med. 2018;91(1):18–26. doi:10.15386/cjmed924
52. Lakoski SG, Jones LW, Krone RJ, Stein PK, Scott JM. Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms. Am Heart J. 2015;170(2):231–241. doi:10.1016/j.ahj.2015.05.014
53. Kadoya M, Koyama H, Kurajoh M, Kanzaki A, KakutaniHatayama M, Okazaki H et al. Sleep, cardiac autonomic function, and carotid atherosclerosis in patients with cardiovascular risks: HSCAA study. Atherosclerosis. 2015;238(2):409–414. doi:10.1016/j.atherosclerosis.2014.12.032
54. Salukhov VV, Kadin DV. Obesity as an oncological risk factor. Literature review. Med Sovet. 2019;4:94–102. doi:10.21518/2079-701X2019-4-94-102. In Russian.
55. Novikov SYu, Shumilov PV, Shestopalov AV, Moreno IG. Pathogenetic mechanisms of arterial hypertension associated with obesity. Pediatria = Pediatrics. 2018;97(3):161–166. doi:10.24110/0031-403X2018-97-3-161-166. In Russian.
56. Rausch LK, Netzer NC, Hoegel J, Pramsohler S. The linkage between creast cancer, hypoxia, and adipose tissue. Front Oncol. 2017;7:211. doi:10.3389/fonc.2017.00211
57. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C et al. Endogenous hormones breast cancer collaborative group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218– 1226. doi:10.1093/jnci/djg022
58. Chagay NB, Mkrtumyan AM. Methylation of estrogens, obesity and breast cancer. Problemy Endokrinologii = Issues of Endocrinology. 2018;64(4):244–251. doi:10.14341/probl9550. In Russian.
59. Ackerman SE, Blackburn OA, Marchildon F, Cohen P. Insights into the link between obesity and cancer. Curr Obes Rep. 2017;6(2):195–203. doi:10.1007/s13679-017-0263-x
60. Frasor J, El-Shennawy L, Stender JD, Kastrati I. NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. Mol Cell Endocrinol. 2015;418(Pt3(03)):235–239. doi:10.1016/j.mce.2014.09.013
61. Zahid H, Simpson ER, Brown KA. Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer. Curr Opin Pharmacol. 2016;31:90–96. doi:10.1016/j.coph.2016.11.003
62. Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025
63. Hamet P. Cancer and hypertension. An unresolved issue. Hypertension. 1996;28(3):321–324. doi:10.1161/01.hyp.28.3.321
64. Zhu Y, Liu X, Ding X, Wang F, Geng X. Telomere and its role in the aging pathways: telomere shortening, cell senescence and mitochondria dysfunction. Biogerontology. 2019;20(1):1–16. doi:10.1007/s10522-018-9769-1
65. van der Rijt S, Molenaars M, McIntyre RL, Janssens GE, Houtkooper RH. Integrating the hallmarks of aging throughout the tree of life: a focus on mitochondrial dysfunction. Front Cell Dev Biol. 2020;8:594416. doi:10.3389/fcell.2020.594416
66. Dvoretskii LI. Iatrogenia in internist practice. Ther Arch. 2019;91(1):121–128. doi:10.26442/00403660.2019.01.000041. In Russian.
67. Tyulyandin SA, Zhukova LG, Koroleva IA, Parokonnaya AA, Semiglazova TYu, Stenina MB et al. Practice guidelines for drug treatment of breast cancer. Malignant tumors. Practice guidelines. 2021;11:09. In Russian.
68. Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J et al. Mechanisms of VEGF (Vascular Endothelial Growth Factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018;71(2):e1-e8. doi:10.1161/HYPERTENSIONAHA.117.10271
69. Boursiquot BC, Zabor EC, Glezerman IG, Jaimes EA. Hypertension and VEGF (Vascular Endothelial Growth Factor) receptor tyrosine kinase inhibition: effects on renal function. Hypertension. 2017: HYPERTENSIONAHA.117.09275. doi:10.1161/HYPERTENSIONAHA.117.09275
70. Neves KB, Rios FJ, van der Mey L, Alves-Lopes R, Cameron AC, Volpe M et al. VEGFR (Vascular Endothelial Growth Factor Receptor) inhibition induces cardiovascular damage via redox-sensitive processes. Hypertension. 2018;71(4):638–647. doi:10.1161/HYPERTENSIONAHA.117.10490
71. Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152–160. doi:10.1016/j.pharmthera.2017.08.012
72. Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121(2):311–319. doi:10.1002/cncr.28972
73. Małyszko J, Małyszko M, Kozlowski L, Kozlowska K, Małyszko J. Hypertension in malignancy-an underappreciated problem. Oncotarget. 2018;9(29):20855–20871. doi:10.18632/oncotarget.25024
74. Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in cancer patients and survivors: epidemiology, diagnosis, and management. JACC CardioOncol. 2019;1(2):238–251. doi:10.1016/j.jaccao.2019.11.009
75. Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides D, Dimopoulos MA et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012;38(5):473–83. doi:10.1016/j.ctrv.2011.09.002
76. Cameron AC, Touyz RM, Lang NN. Vascular complications of cancer chemotherapy. Can J Cardiol. 2016;32(7):852–862. doi:10.1016/j.cjca.2015.12.023
77. Al-Hashmi S, Boels PJ, Zadjali F, Sadeghi B, Sällström J, Hultenby K et al. Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase. PLoS One. 2012;7(1):e30897. doi:10.1371/journal.pone.0030897
78. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–265. doi:10.1038/nrc1317
79. Mohammed T, Singh M, Tiu JG, Kim AS. Etiology and management of hypertension in patients with cancer. Cardiooncology. 2021;7(1):14. doi:10.1186/s40959-021-00101-2
80. Stoter G, Koopman A, Vendrik CP, Struyvenberg A, Sleyfer DT, Willemse PH et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol. 1989;7(8):1099–1104. doi:10.1200/JCO.1989.7.8.1099
81. Hildebrandt MAT, Reyes M, Wu X, Pu X, Thompson KA, Ma J et al. Hypertension susceptibility loci are associated with anthracycline-related cardiotoxicity in long-term childhood cancer survivors. Sci Rep. 2017;7(1):9698. doi:10.1038/s41598-017-09517-2
82. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808–2815. doi:10.1200/JCO.2006.10.4976
Supplementary files
Review
For citations:
Brodskaya T.A., Geltser B.I., Satalkina T.S., Knysh S.V., Shekunova O.I. Arterial hypertension and breast cancer in women: mechanisms of comorbidity and iatrogenic disease. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2022;28(2):147-156. (In Russ.) https://doi.org/10.18705/1607-419X-2022-28-2-147-156
Views:
1437
Email this article 